Case Study: CDR-Life achieves cost-effective clinical development with Certara's QSP modeling solutions

Systems Modeling Delivers Efficiencies and Savings in Clinical Development

CDR-Life, a biotechnology company developing T-cell engagers for cancer, faced the challenge of selecting an optimal first-in-human dose for their therapy. They sought a starting dose that was high enough to potentially show efficacy, which would avoid lengthy dose-escalation trials. CDR-Life partnered with Certara, using their Quantitative Systems Pharmacology (QSP) modeling services to address this.

Certara developed a QSP model based on preclinical data that supported a higher starting dose than traditional methods would allow. This approach was approved by regulators. The result was a significant reduction in both the number of patients needed for the trial and its overall duration, leading to substantial cost savings for CDR-Life in their clinical development.

CDR-Life

Melissa Vrohlings

Translational Science Leader